b<PAGE>

                                UNITED STATES
                      SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C. 20549
                                -------------

                                 FORM 10-QSB

(Mark One)

   /X/   Quarterly report under Section 13 or 15(d) of the Securities Exchange
         Act of 1934.

         For the quarterly period ended January 31, 2000



   / /   Transition report under Section 13 or 15(d) of the Exchange Act.

         For the transition period from _______ to ______

             Commission file number:  001-12531

                             ISONICS CORPORATION
      (Exact name of small business issuer as specified in its charter)

             CALIFORNIA                             77-0338561
             ----------                             ----------
  (State or other jurisdiction of                  (IRS Employer
   incorporation or organization)                 Identification
                                                       No.)

                             5906 MCINTYRE STREET
                            GOLDEN, COLORADO 80403
                            ----------------------
                   (Address of principal executive offices)


                                (303) 279-7900
                                --------------
                         (Issuer's telephone number)

Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes  X   No
                                                              ---      ---

The number of shares outstanding of the registrant's Common Stock, no par value,
was 6,676,691 at March 10, 2000.

Transitional Small Business Disclosure Format (check one):
Yes      No  X
   -----   -----

<PAGE>
                             Isonics Corporation

                              TABLE OF CONTENTS

                                 FORM 10-QSB

<TABLE>
<S>                                                                  <C>

Part I: Financial Information

      Item 1:  Financial Statements

               Condensed Consolidated Balance
                  Sheets as of January 31, 2000
                  and April 30, 1999...................................3
               Condensed Consolidated
                  Statements of Operations for
                  the Three and Nine Month
                  Periods Ended January 31,
                  2000 and 1999........................................5
               Condensed Consolidated
                  Statements of Cash Flows for
                  the Nine Month Periods Ended
                  January 31, 2000 and 1999............................6
               Notes to Condensed Consolidated
                  Financial Statements.................................7

      Item 2:  Management's Discussion and
                  Analysis of Financial
                  Condition and Results of
                  Operations..........................................12

Part II:       Other Information

      Item 6:  Exhibits and Reports on Form 8-K.......................23

Signatures     .......................................................24

</TABLE>

                                       2
<PAGE>

PART I:  FINANCIAL INFORMATION

ITEM 1: CONDENSED FINANCIAL STATEMENTS


                      ISONICS CORPORATION AND SUBSIDIARIES
                      CONDENSED CONSOLIDATED BALANCE SHEETS
                      (IN THOUSANDS, EXCEPT SHARE AMOUNTS)


                                     ASSETS

<TABLE>
<CAPTION>

                                                      (UNAUDITED)
                                                      JANUARY 31,     APRIL 30,
                                                        2000            1999
                                                     ------------   ------------
<S>                                                  <C>            <C>
CURRENT ASSETS:
     Cash and cash equivalents                       $      4,576   $        452
     Accounts receivable (Net of allowance of $82)          1,915            932
     Inventories                                              233            651
     Prepaid expenses and other current assets                 72            160
                                                     ------------   ------------
          Total current assets                       $      6,796   $      2,195
                                                     ------------   ------------

LONG-TERM ASSETS
     Property and equipment, net                              784          1,018
     Goodwill, net                                          3,104          3,388
     Notes receivable from shareholders                         0            130
     Other assets                                              32             75
                                                     ------------   ------------
          Total long-term assets                     $      3,920   $      4,611
                                                     ------------   ------------

TOTAL ASSETS                                         $     10,716   $      6,806
                                                     ============   ============

</TABLE>
          See notes to condensed consolidated financial statements.



                                       3
<PAGE>


                      ISONICS CORPORATION AND SUBSIDIARIES
                      CONDENSED CONSOLIDATED BALANCE SHEETS
                      (IN THOUSANDS, EXCEPT SHARE AMOUNTS)


                      LIABILITIES AND SHAREHOLDERS' EQUITY

<TABLE>
<CAPTION>

                                                                      (UNAUDITED)
                                                                      JANUARY 31,          APRIL 30,
                                                                          2000               1999
                                                                      ------------        ------------
<S>                                                                   <C>                 <C>
CURRENT LIABILITIES:
     Notes payable and line of credit                                  $     24             $  1,136
     Notes payable to related parties                                         0                  922
     Accounts payable                                                     1,364                1,368
     Accrued liabilities                                                  1,341                1,086
                                                                       --------             --------
          Total current liabilities                                    $  2,729             $  4,512
                                                                       --------             --------

SHAREHOLDERS' EQUITY:
     Class A Preferred Stock--no par value. 10,000,000                    2,745                   --
          shares authorized; 1,830,000 shares outstanding
     Common stock--no par value.  20,000,000 shares
          authorized; 6,663,017 shares issued
          and outstanding on January 31, 2000 and 6,607,760
          shares issued and outstanding on April 30, 1999                 6,765                6,795
     Notes receivable from shareholders                                    (210)                (469)
     Accumulated deficit                                                 (1,313)              (4,032)
                                                                       --------             --------
          Total shareholders' equity                                   $  7,987             $  2,294
                                                                       --------             --------

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY                             $ 10,716             $  6,806
                                                                       ========             ========

</TABLE>

            See notes to condensed consolidated financial statements.


                                       4
<PAGE>

                    ISONICS CORPORATION AND SUBSIDIARIES
               CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                    (IN THOUSANDS, EXCEPT PER SHARE DATA)
                                 (UNAUDITED)

<TABLE>
<CAPTION>

                                                      THREE MONTHS ENDED     NINE MONTHS ENDED
                                                          JANUARY 31,            JANUARY 31,
                                                     --------------------    --------------------
                                                       2000        1999        2000        1999
                                                     --------    --------    --------    --------
<S>                                                  <C>         <C>         <C>         <C>
Net revenues                                         $  3,571    $  6,670    $ 11,115    $ 14,309
Cost of revenues                                        2,924       5,393       8,792      11,575
                                                     --------    --------    --------    --------
          Gross margin                                    647       1,277       2,323       2,734

Operating expenses:
  Selling, general and administrative                   1,284         826       3,117       2,444
  Research and development                                587         250         919         962
  Restructuring and office closure                         (3)         --          60         708
                                                     --------    --------    --------    --------
    Total operating expenses                            1,868       1,076       4,096       4,114
                                                     --------    --------    --------    --------
Operating income (loss)                                (1,221)        201      (1,773)     (1,380)
                                                     --------    --------    --------    --------
Other income (expense):
  Foreign exchange                                        (64)        131         (64)         35
  Interest income                                           5           9          55          21
  Other income                                          5,184          --       5,296          --
  Interest expense                                       (100)        (87)       (325)       (236)
                                                     --------    --------    --------    --------
    Total other income (expense), net                   5,025          53       4,962        (180)
                                                     --------    --------    --------    --------
Income (loss) before income taxes                       3,804         254       3,189      (1,560)
Income tax expense                                        470         177         471         197
                                                     --------    --------    --------    --------
NET INCOME (LOSS)                                    $  3,334    $     77    $  2,718    $ (1,757)
                                                     ========    ========    ========    ========
NET INCOME (LOSS) PER SHARE--BASIC
Net income (loss) per share                          $   0.50    $   0.01    $   0.41    $  (0.29)
Shares used in computing per share information          6,615       6,216       6,610       6,120

NET INCOME (LOSS) PER SHARE--DILUTED
Net income (loss) per share                          $   0.34    $   0.01    $   0.31    $  (0.29)
Shares used in computing per share information          9,770       6,918       8,906       6,120

</TABLE>

            See notes to condensed consolidated financial statements.


                                       5
<PAGE>


                     ISONICS CORPORATION AND SUBSIDIARIES
               CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                               (IN THOUSANDS)
                                 (UNAUDITED)


<TABLE>
<CAPTION>
                                                                NINE MONTHS ENDED
                                                                   JANUARY 31,
                                                               ------------------
                                                                2000        1999
                                                               -------    -------
<S>                                                            <C>        <C>
Net cash (used in) provided by operating activities            $(2,904)   $   146


CASH FLOWS FROM INVESTING ACTIVITIES:
     Purchase of Chemotrade, net of cash acquired                   --       (546)
     Sale of depleted zinc business                              6,730         --
     Purchases of property and equipment                           (20)      (120)
                                                               -------    -------
          Cash provided by (used in) investing activities      $ 6,710    $  (666)
                                                               -------    -------

CASH FLOWS FROM FINANCING ACTIVITIES:
     Net change in line of credit                                 (513)       931
     Proceeds from issuance of notes payable                        75        500
     Repayments of notes payable                                (1,494)    (1,714)
     Proceeds from issuance of common stock                         --         17
     Proceeds from issuance of Class A Preferred Stock           2,250         --
     Payments of debt issuance costs                                --        (30)
                                                               -------    -------
          Cash provided by (used in) financing activities      $   318    $  (296)
                                                               -------    -------

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS:            4,124       (816)
     Cash and cash equivalents at beginning of period              452      1,044
                                                               -------    -------
     Cash and cash equivalents at end of period                $ 4,576    $   228
                                                               =======    =======

Supplemental disclosure of cash flow information:
     Cash paid during the period for:
          Interest                                             $   252    $   149
                                                               =======    =======
          Income taxes                                         $    53    $   242
                                                               =======    =======

Supplemental disclosure of noncash investing and
     financing activities:
          Accounts payable converted into
              notes payable                                    $   243    $    --
          Liabilities converted into Class A
              Preferred Stock                                      495         --
          Equipment acquired under capital lease                    --         14
          Issuance of warrants in conjunction
              with notes payable                                   245         --
          Retirement of Common Stock by
              shareholders to pay off subscriptions                275         --
                                                               =======    =======

          Purchase of Chemotrade:
               Cash paid, net of cash acquired                            $   546
               Stock issued to sellers                                        894
               Notes payable issued to sellers                              1,750
               Liabilities assumed                                          1,598
                                                                          -------
                    Assets acquired (including
                       goodwill of $3,385)                                $ 4,788
                                                                          =======

</TABLE>

            See notes to condensed consolidated financial statements.



                                       6
<PAGE>

                     ISONICS CORPORATION AND SUBSIDIARIES
             NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS


BASIS OF PRESENTATION

The accompanying condensed consolidated financial statements of Isonics
Corporation and Subsidiaries (the "Company" or "Isonics") as of January 31,
2000, and for the three and nine months ended January 31, 2000, and 1999, have
been prepared on the same basis as the annual audited financial statements. In
the opinion of management, such unaudited information includes all adjustments
(consisting only of normal recurring accruals) necessary for a fair presentation
of this interim information. Operating results and cash flows for interim
periods are not necessarily indicative of results for the entire year. The
information included in this report should be read in conjunction with our
audited financial statements and notes thereto included in our Annual Report on
Form 10-KSB for the year ended April 30, 1999.


NET INCOME (LOSS) PER SHARE

Net income (loss) per share is based on the weighted average number of common
and common equivalent shares outstanding during the period. Common equivalent
shares include common stock options, warrants and convertible preferred
stock. Basic net income (loss) per share is computed by dividing net income
(loss) by the number of weighted average common shares outstanding. Diluted
net income (loss) per share reflects potential dilution from outstanding
stock options and warrants using the treasury stock method, and convertible
preferred stock using the if-converted method. A total of approximately
1,513,000 outstanding stock options and warrants have been excluded from the
diluted earnings per share calculation, as the inclusion would be
anti-dilutive. An additional 4,000,000 warrants were excluded from the
calculation, as the issuance of the warrants is contingent upon the delivery
of silicon-28 per the terms of the Eagle-Picher Transaction.

RECONCILIATION OF EARNINGS PER SHARE CALCULATIONS

<TABLE>
<CAPTION>

                                           THREE MONTHS ENDED  NINE MONTHS ENDED
                                               JANUARY 31,       JANUARY 31,
                                           ------------------  -----------------
          NUMERATOR                          2000     1999       2000     1999
                                           -------   -------   -------   -------
<S>                                        <C>       <C>       <C>       <C>
Net income (loss)                          $ 3,334        77     2,718    (1,757)
Preferred stock dividends                       --        --        --        --
                                            -------   -------   -------   -------

Net income (loss) used in computing
basic income (loss) per common share       $ 3,334   $    77   $ 2,718   $(1,757)

Preferred stock dividends                       --        --        --        --
                                           -------   -------   -------   -------
Net income (loss) used in computing
diluted income (loss) per common share     $ 3,334        77     2,718    (1,757)
                                           =======   =======   =======   =======


         DENOMINATOR
Weighted average common shares
outstanding during the period                6,615     6,216     6,610     6,120

Dilutive effect of conversion of
preferred stock                              1,830        --     1,220        --
                                           -------   -------   -------   -------
Dilutive effect of options and
warrants using the treasury stock method     1,325       702     1,076        --


                                       7
<PAGE>

                                           -------   -------   -------   -------
Shares used in computing diluted
income (loss) per common share               9,770     6,918     8,906     6,120
                                           =======   =======   =======   =======

</TABLE>


                                       8
<PAGE>

                     ISONICS CORPORATION AND SUBSIDIARIES
       NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)


INVENTORIES

Inventories consist of (in thousands):

<TABLE>
<CAPTION>

                                JANUARY 31,      APRIL 30,
                                   2000            1999
                                -----------      ----------
<S>                             <C>             <C>
Finished goods                    $138            $420
Work in progress                    95              --
Raw materials                       --             231
                                  ----            ----
     Total inventories            $233            $651
                                  ====            ====
</TABLE>

NOTES PAYABLE - RELATED PARTIES

Two notes were issued to each of the sellers of Chemotrade GmbH and subsidiary
as consideration for a portion of the purchase price. The first note was repaid
in August 1998. A partial payment of approximately $550 thousand was paid in
June 1999, on the second note. The remaining balance of approximately $343
thousand including interest, was refinanced and was originally payable July 31,
2000. The new interest rate was 12% per annum. In addition, approximately 70,000
warrants (five-year, $3.00 strike price) were issued in June 1999, in
conjunction with the refinancing. The fair value of these warrants was
determined to be $157 thousand, using the Black-Scholes option pricing model,
and this value has been amortized as additional interest expense. This note, and
all accrued interest, was paid in December 1999, with proceeds made available
from the Eagle-Picher Transaction, described in more detail below in the
paragraph entitled "SALE OF DEPLETED ZINC BUSINESS."


RESTRUCTURING AND OFFICE CLOSURE COSTS

On October 31, 1998, the Company announced a restructuring of its operations and
relocation of its headquarters from San Jose, California to Golden, Colorado,
the location of the Company's subsidiary, Interpro. As of January 31, 2000, the
only significant restructuring cost remaining is the lease payments on the
former San Jose office. This liability, net of sublease income, is estimated to
be approximately $51 thousand, and will be paid over the next four years.


SIGNIFICANT CUSTOMERS

At January 31, 2000, one customer accounted for 33% of total accounts
receivable. The same customer accounted for approximately 37% of net revenues
during the three months ended January 31, 2000, and for approximately 18% of net
revenues during the nine months ended January 31, 2000. The same customer
accounted for approximately 13% of net revenues during the three months ended
January 31, 1999, and 17% of net revenues during the nine months ended January
31, 1999.


                                       9
<PAGE>

                      ISONICS CORPORATION AND SUBSIDIARIES
        NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)


PREFERRED STOCK ISSUANCE

On July 29, 1999, the Company completed a private placement financing to
accredited investors and certain creditors valued in total at $2.745 million.
The Company issued 1,830,000 units, each consisting of one share of Series A
Convertible Preferred Stock and one warrant. The Company received $2,250,000
cash proceeds and converted $495,000 of long-term debt and other obligations to
equity. Each share of the Series A Convertible Preferred Stock is convertible
into one share of the Company's common stock at a conversion price of $1.50. The
liquidation preference for the Series A Convertible Preferred Stock is $1.50.
Each warrant allows the investor to purchase one share of the Company's common
stock for $3.75 through July 29, 2002.

In addition to converting $495,000 of existing debt and other obligations into
equity as part of the private placement, the Company:

-  issued 500,000 warrants to purchase shares of the Company's common stock to
   an investment banker for service rendered in this placement. The warrants are
   exercisable at $3.75 per share through July 29, 2002.

-  extended the payment due date for the remaining balance on the Chemotrade
   acquisition note to July 2000 and extended the payment due date for certain
   unsecured promissory notes to January 2000. These notes were repaid in full,
   including accrued interest, in December 1999.


SEGMENT INFORMATION (IN THOUSANDS)

<TABLE>
<CAPTION>
                                       THREE MONTHS ENDED       NINE MONTHS ENDED
                                            JANUARY 31,             JANUARY 31,
                                       -------------------     -------------------
                                        2000         1999        2000        1999
                                       -------     -------     -------     -------
<S>                                    <C>         <C>         <C>         <C>
Segment revenues:
  Isotope products                     $ 3,271     $ 5,985     $10,098     $11,991

  Contract research and
    development services and other         300         685       1,017       2,318
                                       -------     -------     -------     -------
    Total                              $ 3,571     $ 6,670     $11,115     $14,309

</TABLE>


                                       10
<PAGE>

                      ISONICS CORPORATION AND SUBSIDIARIES
        NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

<TABLE>
<CAPTION>
                                       THREE MONTHS ENDED         NINE MONTHS ENDED
                                           JANUARY 31,               JANUARY 31,
                                       --------------------      --------------------
                                         2000        1999         2000          1999
                                       -------      -------      -------      -------
<S>                                    <C>          <C>          <C>          <C>
Segment operating (loss) income:
  Isotope products                     $(1,058)     $  (340)     $(1,387)     $(1,217)
  Contract research and
    development services and other        (163)         541         (386)        (163)
                                       -------      -------      -------      -------
    Total                              $(1,221)     $   201      $(1,773)     $(1,380)


</TABLE>
<TABLE>
<CAPTION>
                                     January 31,
                                        2000
                                     -----------
<S>                                  <C>
Identifiable Assets:
  Isotope products                     $ 9,750
  Contract research and
    development services and other         966
                                       -------
    Total                              $10,716

</TABLE>

A summary of operations by geographic area is as follows:


<TABLE>
<CAPTION>

                                  THREE MONTHS ENDED          NINE MONTHS ENDED
                                      JANUARY 31,                JANUARY 31,
                                ------------------------    -----------------------
                                   2000          1999          2000          1999
                                ----------    ----------    ---------     ---------
<S>                             <C>           <C>           <C>           <C>
Net revenues:
     United States              $    1,098    $    3,908    $   3,904     $   6,964
     Germany                         2,473         2,762        7,211         7,345
                                ----------    ----------    ---------     ---------
          Total                 $    3,571    $    6,670    $  11,115     $  14,309



<CAPTION>
                                  THREE MONTHS ENDED          NINE MONTHS ENDED
                                      JANUARY 31,                JANUARY 31,
                                ------------------------    -----------------------
                                    2000          1999         2000          1999
                                ----------    ----------    ---------     ---------
<S>                             <C>           <C>           <C>           <C>
Operating (loss) income:
     United States              $  (1,258)    $      593    $ (1,982)     $ (1,107)
     Germany                           37           (392)        209          (273)
                                ----------    ----------    ---------     ---------
          Total                 $  (1,221)    $      201    $ (1,773)     $ (1,380)

</TABLE>


                                       11
<PAGE>

                      ISONICS CORPORATION AND SUBSIDIARIES
        NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

<TABLE>
<CAPTION>
                                January 31,
                                   2000
                                -----------
<S>                             <C>
Identifiable Assets:
     United States              $     8,798
     Germany                          1,918
                                -----------
          Total                 $    10,716

</TABLE>

SALE OF DEPLETED ZINC BUSINESS

On December 1, 1999, we sold our depleted zinc business to Eagle-Picher
Technologies, LLC. ("Eagle-Picher") for approximately $8.2 million, of which
$6.7 million was paid on December 1, 1999. Additionally, we signed a long-term
isotope supply agreement with Eagle-Picher, and Eagle-Picher will supply us in
2000 with 200 kilograms of silicon-28 to be used in research and development
activities. We also gave Eagle-Picher a warrant to obtain 4,000,000 shares of
our common stock. The warrants are contingent upon the delivery of silicon-28 by
Eagle-Picher. As silicon-28 is delivered we will record the value of the silicon
and the warrants proportionately (20,000 warrants per kilogram), at a value of
$25.00 per gram. This is the price we most recently paid for silicon-28 from
another supplier.

The balance of $1.5 million is payable in three annual installments of $500
thousand. These installments are contingent upon the performance of an
unaffiliated supplier of depleted zinc whose contract with us was assigned to
Eagle-Picher. We will recognize the contingent gain on a straight-line basis
over the thirty-six month period, approximately $41,500 per month, as the
supplier performs under the contract. Two months, or approximately $83,000,
has been recognized in the quarter ended January 31, 2000.

We do not anticipate significant revenues from sales of silicon-28 based
products in the fiscal year ended April 30, 2000. We are collaborating with
academia and industry to evaluate the benefits of isotopically pure silicon-28.
We believe that if evaluations demonstrate the commercial feasibility of one or
more products, demand could emerge in certain segments of the semiconductor
market. We can offer no assurance, however, that these evaluations will
demonstrate the commercial feasibility of any products, that we will be able to
commercialize any such products, or that a market will emerge for any such
products.



                                       12
<PAGE>

ITEM 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS


THE STATEMENTS CONTAINED IN THIS REPORT ON FORM 10-QSB THAT ARE NOT PURELY
HISTORICAL ARE FORWARD LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF
THE SECURITIES ACT OF 1933 AND SECTION 21E OF THE SECURITIES EXCHANGE ACT OF
1934, INCLUDING STATEMENTS REGARDING OUR EXPECTATIONS, HOPES, INTENTIONS OR
STRATEGIES REGARDING THE FUTURE. FORWARD-LOOKING STATEMENTS INCLUDE: STATEMENTS
REGARDING FUTURE PRODUCTS OR PRODUCT DEVELOPMENT; STATEMENTS REGARDING FUTURE
SELLING, GENERAL AND ADMINISTRATIVE COSTS AND RESEARCH AND DEVELOPMENT SPENDING
AND OUR PRODUCT DEVELOPMENT STRATEGY; AND STATEMENTS REGARDING FUTURE CAPITAL
EXPENDITURES AND FINANCING REQUIREMENTS. ALL FORWARD-LOOKING STATEMENTS INCLUDED
IN THIS DOCUMENT ARE BASED ON INFORMATION AVAILABLE TO US ON THE DATE HEREOF,
AND WE UNDERTAKE NO OBLIGATION TO UPDATE ANY SUCH FORWARD-LOOKING STATEMENTS. IT
IS IMPORTANT TO NOTE THAT OUR ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THOSE
IN SUCH FORWARD-LOOKING STATEMENTS.


OVERVIEW

Founded in 1992, Isonics Corporation ("Isonics" or the "Company") is a specialty
chemical and advanced materials company, which develops and commercializes
products based on stable isotopes. Stable isotopes are ultra pure materials
engineered at the molecular level to provide enhanced performance properties in
semiconductors, lasers and high performance lighting and energy production.
Stable isotopes are also widely used in basic research, pharmaceutical
development and drug design, as well as in medical diagnostics and imaging. By
replacing materials traditionally used in these industries with isotopically
engineered versions of the same materials, product performance, safety, and
economics can be enhanced significantly. Using state-of-the-art technology, we
produce a wide range of enriched stable isotopes, which are then converted into
products, which meet the specialized needs of our customers.

Originally, our core business was the production and supply of depleted zinc
("DZ"), a non-radioactive stable isotope, to the energy industry. In fiscal
1996, we expanded our business scope to include development of isotopically
engineered materials for the medical research, medical diagnostic and
semiconductor industries. The acquisition of Chemotrade GmbH ("Chemotrade") in
1998 added radioactive isotopes (or radioisotopes) to our available products. As
a result of the sale of our depleted zinc business in December 1999, (see
discussion below) our revenues in the future will depend on our success in
developing and selling products in the semiconductor and stable and radioactive
isotope markets.

International Process Research Corporation ("Interpro", doing business as
Colorado Minerals Research Institute) is a contract research and development and
materials processing company and is developing new, lower cost technologies to
better meet our customers' needs. Interpro generates the majority of its
revenues from contract research and process development engagements.

Chemotrade is headquartered in Dusseldorf, Germany, and its subsidiary is
located in Leipzig, Germany. Chemotrade is a value-added re-seller of stable and
radioactive isotopes. It supplies radioactive isotopes for pharmaceutical and
industrial research as well as for industrial and medical imaging, calibration
sources and for brachytherapy applications. Chemotrade also distributes
calibration sources, manufactured by duPont with Chemotrade supplied radioactive
isotopes, in Germany and other European countries.



                                       13
<PAGE>

ITEM 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS (CONTINUED)

Additionally, Chemotrade supplies various stable isotope labeled compounds for
pharmaceutical research and drug design, as well as oxygen-18 for use in
producing a radioisotope used in positron emission tomography. Chemotrade's
market is primarily Europe but sales are also made to North America and Asia.

Prior to June 1998, substantially all of our net revenues in any particular
period were attributable to a limited number of customers and sales of depleted
zinc and other stable isotopes. We have historically operated with little
backlog. With the acquisition of Chemotrade we added radioisotopes to our
product mix, and consistent with our historical experience, our quarterly
results have been materially affected by the size, timing and quantity of orders
and product shipments during a given quarter.

On December 1, 1999, we sold our depleted zinc business to Eagle-Picher
Technologies, LLC ("Eagle-Picher") for approximately $8.2 million of which $6.7
million was paid on December 1, 1999. Additionally, we signed a long-term
isotope supply agreement with Eagle-Picher, and Eagle-Picher will supply us with
200 kilograms of silicon-28 in 2000. We also gave Eagle-Picher a warrant to
obtain 4,000,000 shares of our common stock.

As a result of the sale of the depleted zinc business, we anticipate lower
revenues in future quarters and a lost or delayed sale of radioisotopes could
have a significant impact on our operating results for a particular period,
and such fluctuations could materially and adversely affect our business,
financial condition and results of operations.

RESULTS OF OPERATIONS

The following table sets forth, for the periods indicated, certain statement of
operations data expressed as a percentage of net sales. The table and the
discussion below should be read in conjunction with the condensed consolidated
financial statements and the notes thereto appearing elsewhere in this report.

<TABLE>
<CAPTION>

                                             THREE MONTHS ENDED     NINE MONTHS ENDED
                                                 JANUARY 31,            JANUARY 31
                                             ------------------     ------------------
                                              2000        1999       2000        1999
                                             ------      ------     ------      ------
<S>                                          <C>         <C>        <C>         <C>
Net revenues                                 100.0%      100.0%     100.0%      100.0%
Cost of revenues                              81.9        80.9       79.1        80.9
                                             -----       -----      -----       -----
     Gross margin                             18.1        19.1       20.9        19.1
                                             -----       -----      -----       -----

Operating expenses:
     Selling, general & Administrative        36.0        12.4       28.0        17.1
     Research & development                   16.4         3.7        8.3         6.7
     Restructuring & office closure           (0.1)       --          0.5         4.9
                                             -----       -----      -----       -----
          Total operating expenses            52.3        16.1       36.8        28.7
                                             -----       -----      -----       -----
Operating income (loss)                      (34.2)        3.0      (15.9)       (9.6)
                                             =====       =====      =====       =====
Other income (expense) net                   140.7         0.8       44.6        (1.3)
                                             -----       -----      -----       -----
Income (loss) before income taxes            106.5         3.8       28.7       (10.9)
                                             -----       -----      -----       -----
Income tax expense                            13.2         2.7        4.2         1.4
                                             -----       -----      -----       -----
NET INCOME (LOSS)                             93.3%        1.1%      24.5%      (12.3)%
                                             =====       =====      =====       =====

</TABLE>


                                       14
<PAGE>

ITEM 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS (CONTINUED)


NET REVENUES

As a result of the sale of the depleted zinc business to Eagle-Picher on
December 1, 1999, revenues will be decreased on an annual basis by approximately
$6.0 million dollars. The impact on the fiscal year ended April 30, 2000, should
be somewhat less as the sale occurred seven months into the fiscal year.

Net revenues for the three months ended January 31, 2000, were $3.571
million, a decrease of approximately 46.5% or $3.099 million over $6.670
million for the same period in the prior fiscal year. The decrease is
primarily because our net revenues from isotope product sales decreased
approximately $2.714 million for the three months ended January 31, 2000, to
approximately $3.271 million from approximately $5.985 million in the
comparable period of the prior year. Net revenues from radioisotope sales
decreased approximately $856 thousand for the three months ended January 31,
2000, compared to the three months ended January 31, 1999, to approximately
$2.445 million. Net revenues from stable isotope sales decreased
approximately $1.858 million for the three months ended January 31, 2000,
compared to the three months ended January 31, 1999, to approximately $826
thousand. Net revenues from contract research and development services sales
as well as other sources of sales decreased approximately $385 thousand for
the three months ended January 31, 2000, to approximately $300 thousand from
approximately $685 thousand in the comparable period of the prior year. Net
revenues from stable isotope and radioisotope sales varied considerably from
the same quarter in the prior fiscal year primarily because of timing of
large depleted zinc and radioisotope sales orders and shipments. Because of
the Eagle-Picher transaction there were no significant depleted zinc sales in
the quarter ended January 31, 2000.

Net revenues for the nine months ended January 31, 2000, were $11.115 million, a
decrease of approximately 22% or $3.194 million from $14.309 million for the
same period in the prior fiscal year. The decrease is primarily because our net
revenues from contract research and development engagements and other sources of
sales decreased approximately $1.301 million for the nine months ended January
31, 2000, to approximately $1.017 million from approximately $2.318 million in
the comparable period of the prior year. Net revenues from isotope product sales
also decreased approximately $1.893 million for the nine months ended January
31, 2000, to approximately $10.098 million from approximately $11.991 million in
the comparable period of the prior year. Net revenues from radioisotope sales
decreased approximately $513 thousand for the nine months ended January 31,
2000, compared to the nine months ended January 31, 1999, to approximately
$5.001 million. Net revenues from stable isotope sales decreased approximately
$1.380 million for the nine months ended January 31, 2000, compared to the nine
months ended January 31, 1999, to approximately $5.097 million. Net revenues
from stable isotopes and radioisotope sales varied because of the timing and
size of large depleted zinc and radioisotope sales orders and shipments. Because
of the Eagle-Picher transaction there were no significant depleted zinc sales in
the last two months of the nine-month period ended January 31, 2000, and there
will be no revenues for the remainder of the fiscal year ending April 30, 2000.


                                       15
<PAGE>

ITEM 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS (CONTINUED)

We do not anticipate significant revenues from sales of silicon-28 based
products in the fiscal year ended April 30, 2000. We are collaborating with
academia and industry to evaluate the benefits of isotopically pure silicon-28.
We believe that if evaluations demonstrate the commercial feasibility of one or
more products, demand could emerge in certain segments of the semiconductor
market. We can offer no assurance, however, that these evaluations will
demonstrate the commercial feasibility of any products, that we will be able to
commercialize any such products, or that a market will emerge for any such
products.


GROSS MARGIN

As a result of the sale of the depleted zinc business to Eagle-Picher on
December 1, 1999, gross margin will be decreased on an annual basis by
approximately $1.0 million dollars. The impact on the fiscal year ended April
30, 2000 should be somewhat less as the sale occurred seven months into the
fiscal year. As a percentage of revenues gross margin should not change
significantly.

Gross margin for the three months ended January 31, 2000, decreased to
approximately 18.1% of net revenues from approximately 19.1% for the same period
in the prior fiscal year. The decrease is primarily because of a change in
product mix sold during the quarter as discussed above. Gross margin for the
nine months ended January 31, 2000, increased to approximately 20.9% of net
revenues from approximately 19.1% for the same period in the prior fiscal year.
The increase is primarily because of a change in product mix sold during the
nine month period as discussed above.


SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

As a result of the sale of the depleted zinc business to Eagle-Picher on
December 1, 1999, selling, general and administrative expenses will be decreased
on an annual basis by approximately $100 thousand dollars. The impact on the
fiscal year ended April 30, 2000 should be somewhat less as the sale occurred
seven months into the fiscal year. We anticipate that, in general, selling,
general and administrative expenses will remain relatively stable because of
cost contols implemented throughout the Company during the past twelve months.
As a percentage of revenues selling, general and administrative expenses should
increase, as revenues will be significantly lower.

Selling, general and administrative expenses increased $458 thousand or 55.4% to
approximately $1.284 million, or approximately 36.0% of net revenues for the
three months ended January 31, 2000, from $826 thousand, or 12.4% of net
revenues in the comparable period of the prior year. The dollar increase for the
quarter ended January 31, 2000, was primarily attributable to increased usage of
professional services including legal, business development and accounting
services, and compensation expense related to one-time bonuses associated with
the Eagle-Picher transaction paid to certain members of senior management. The
percentage increase was primarily caused by much lower revenues during the
quarter ended January 31, 2000.


                                       16
<PAGE>

ITEM 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS (CONTINUED)

Selling, general and administrative expenses increased $673 thousand or 27.5% to
approximately $3.117 million, or approximately 28.0% of net revenues for the
nine months ended January 31, 2000, from $2.444 million, or 17.1% of net
revenues in the comparable period of the prior year. The dollar increase for the
nine months ended January 31, 2000, was primarily attributable to increased
usage of professional services including legal, business development and
accounting services, and compensation expense related to one-time bonuses
associated with the Eagle-Picher transaction paid to certain members of senior
management. The percentage increase was primarily caused by the same factors and
lower revenues.


RESEARCH AND DEVELOPMENT

Research and development expenses will not be significantly affected by the sale
of the depleted zinc business to Eagle-Picher on December 1, 1999, because we
had not spent significant funds on depleted zinc research and development in the
last fiscal year, and did not have plans for any significant future research and
development expenditures. However, as a percentage of revenues research and
development expenses should increase, as revenues will be significantly lower.

Research and development expenses increased approximately $337 thousand, or
approximately 134.8%, to $587 thousand for the quarter ended January 31, 2000,
from $250 thousand for the comparable period in fiscal 1999, while increasing on
a percentage basis to approximately 16.4% of net revenues from approximately
3.7%. The dollar increase during the quarter ended January 31, 2000, was
primarily because of research and development costs associated with the
development of isotopically pure silicon wafers.

As described above, we signed a long-term isotope supply agreement with
Eagle-Picher, and Eagle-Picher will supply us with 200 kilograms of
silicon-28 in 2000. The silicon-28 will be used to further development of our
semiconductor materials business. We also gave Eagle-Picher a warrant to
obtain 4,000,000 shares of our common stock. The warrants are contingent upon
the delivery of silicon-28 by Eagle-Picher. The anticipated value of the 200
kilograms is approximately $5,000,000. As we use the silicon-28 in our
research and development activities, we will recognize an expense of
approximately $25.00 per gram, as this is the price we most recently paid for
silicon-28 from another supplier. As silicon-28 is delivered we will record
the warrants proportionately (20,000 warrants per kilogram).

Research and development expenses decreased by approximately $43 thousand, or
approximately 4.5%, to $919 thousand for the nine months ended January 31, 2000,
from $962 thousand for the comparable period in fiscal 1999, while increasing on
a percentage basis to approximately 8.3% of net revenues from approximately
6.7%. The percentage increase during the nine months ended January 31, 2000, was
primarily because of lower revenues as described above. The absolute dollar
expenditures are comparable year over year, however, more emphasis is now being
placed on semiconductor materials development.

We believe that the development and introduction of new product applications is
critical to our future success and we expect that research and development
expenses will increase (as measured in dollars), in the near term because of the
timing of material usage and outside services, but will likely continue to vary
as a percentage of revenues because of the timing and amount of future revenues.


                                       17
<PAGE>

ITEM 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS (CONTINUED)


RESTRUCTURING AND OFFICE CLOSURE

On October 31, 1998, we announced a restructuring of our operations and
relocation of our headquarters to Golden, Colorado, the location of our
subsidiary, Interpro. We recorded a $708 thousand charge in connection with the
restructuring.

As of January 31, 2000, the only significant restructuring cost remaining is the
lease payments on the former San Jose, California office, which has been sublet
for the remaining term of our lease. The net liability is estimated to be
approximately $51 thousand and will be incurred over the next four years. The
$60 thousand expense in the nine months ending January 31, 2000, was primarily
related to moving costs incurred by two senior executives.


OTHER INCOME (EXPENSE), NET

Interest expense is expected to be significantly lower in future periods as
several notes payable were paid with a portion of the cash proceeds received
from the sale of the depleted zinc business to Eagle-Picher on December 1, 1999.

Other income (expense), net includes interest income and expense, amortization
of debt issuance costs and the fair value of warrants issued in connection with
debt, and foreign currency gains and losses. Other income, net increased by
approximately $4.972 million, to $5.025 million, for the quarter ended January
31, 2000, from other income, net of approximately $53 thousand, for the
comparable period of the previous fiscal year. The Eagle-Picher transaction
resulted in a gain of $5.172 million in other income.

Other income (expense), net increased by approximately $5.142 million, to $4.962
million, for the nine months ended January 31, 2000, from other (expense), net
of approximately $180 thousand, for the comparable period of the previous fiscal
year. The Eagle-Picher transaction resulted in $5.172 million in other income.
Additionally, an increase in other income of approximately $112 thousand was due
to a favorable settlement of an outstanding contingency. Foreign currency
exchange losses increased by approximately $99 thousand for the nine months
ended January 31, 2000.


INCOME TAXES

We realized a gain on the sale of our depleted zinc business of approximately
$5.2 million. The tax effect of this sale, net of tax loss carryforwards
available is estimated to be approximately $435 thousand. Additionally, there
was income tax expense for the quarters ended January 31, 2000, and January 31,
1999, of $35 thousand and $177 thousand respectively, and income tax expense for
the nine months ended January 31, 2000 and 1999, of $36 thousand and $197
thousand, respectively, related to income generated by our Germany-based
subsidiary, Chemotrade.


                                       18
<PAGE>

ITEM 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS (CONTINUED)


LIQUIDITY AND CAPITAL RESOURCES

As a result of the sale of the depleted zinc business to Eagle-Picher on
December 1, 1999, liquidity has been significantly improved.

Our principal sources of funding have been cash from borrowed funds and sales
of preferred stock. We used cash in operating activities of approximately
$2.904 million and generated cash of $146 thousand, during the nine months
ended January 31, 2000, and 1999, respectively. Cash used in operating
activities during the nine months ended January 31, 2000 was principally the
result of a net loss of approximately $2.454 million before the gain of
approximately $5.172 million resulting from the Eagle-Picher Transaction, and
increase in net operating assets. Cash generated by operating activities
during the nine months ended January 31, 1999, was principally the result of
a net loss of $1.757 million, reduced by non-cash charges and decreases in
net operating assets.

Our investing activities generated cash of $6.710 million for the nine months
ended January 31, 2000, primarily because of the sale of our depleted zinc
business to Eagle-Picher. Our investing activities used cash of $666 thousand
for the nine months ended January 31, 1999, primarily for purchases of property
and equipment and $546 thousand was also used during the nine months ended
January 31, 1999 for the purchase of our subsidiary Chemotrade.

Financing activities generated cash of $318 thousand during the nine months
ended January 31, 2000, and used cash of $296 thousand during the comparable
period of the previous fiscal year. Cash provided by financing activities
during the nine months ended January 31, 2000, resulted primarily from the
issuance of convertible preferred stock for cash of $2.250 million, and
proceeds from the issuance of long-term debt of $75 thousand. Net repayments
on the revolving line of credit of $513 thousand, and repayments of debt of
$1.494 million were the primary uses of cash during the nine-month period
ended January 31, 2000. Cash used during the nine months ended January 31,
1999, resulted primarily from repayments of debt of $1.714 million, offset by
net borrowings on the revolving line of credit of $931 thousand and proceeds
of $500 thousand from the issuance of long-term debt.

At January 31, 2000, we had approximately $4.576 million of cash and cash
equivalents, an increase of approximately $4.124 million, compared to $452
thousand as of April 30, 1999. At January 31, 2000, we had positive working
capital of approximately $4.067 million, an increase of approximately $6.384
million from negative working capital of approximately $2.317 million April 30,
1999. The increase is primarily the result of proceeds from the issuance of
preferred stock in July 1999 and the Eagle-Picher transaction.

During the nine months ended January 31, 2000, we issued approximately $2.745
million in convertible preferred stock. Cash proceeds totaled approximately
$2.250 million and conversion of notes payable and other obligations to
preferred stock totaled approximately $0.495 million. This convertible preferred
stock placement is described in detail in the Form 8-K we filed on August 11,
1999.


                                       19
<PAGE>

ITEM 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS (CONTINUED)

At April 30, 1999, and subsequently until December 1, 1999, we were in default
of our borrowing agreements with Coast Business Credit ("Coast"), and on
December 1, 1999, we had approximately $215 thousand of outstanding borrowings.
We have used some of the proceeds of the depleted zinc business sale described
above to pay off the Coast borrowings and our relationship with Coast has been
terminated. We currently have no borrowing agreements in place with any lenders
or similar organizations.

We believe that the cash proceeds from the recent sale of our depleted zinc
business will be sufficient for us to meet our cash needs for the next twelve
months. However, our long-term capital requirements will only be met if we are
able to generate profits from operations and positive cash flows, or develop new
sources of financing of which there can be no assurance.


FACTORS THAT MAY AFFECT FUTURE RESULTS

In evaluating our business, prospective investors should carefully consider the
following factors in addition to the other information presented in this report
and in our other reports filed with the SEC that attempt to advise interested
parties of the risks and factors that may affect our business.

Following the sale of our depleted zinc business, our primary risk is our
reliance on products that have to date not produced significant revenues. We
operate with little backlog and a significant portion of our net revenues have
been, and we believe will continue to be, derived from a limited number of
orders that are processed and shipped in the same quarter in which the orders
are received. These orders being primarily for radioisotopes. The timing of such
orders and their fulfillment has caused, and is likely to continue to cause,
material fluctuations in our operating results. Our expense levels are
relatively fixed, and as has been the case in prior quarters, these factors will
affect our operating results for future periods.


RELATIONSHIP WITH CERTAIN SUPPLIERS AND AVAILABILITY OF RAW MATERIALS

We depend on an isotope enrichment plant, located in Russia, which is owned by
the Ministry of Atomic Energy of the Russian Federation (the "Ministry"), which
is part of the cabinet of the government of the Russian Federation, for most of
our stable and radioisotopes. We signed an agreement with the commercial
department of the Ministry to purchase certain isotope separation services
through 2001. Disruption or termination of services provided by the Ministry
could have a material and adverse affect upon our financial condition and
results of operations.


                                       20
<PAGE>

ITEM 2:  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (CONTINUED)


OPERATIONS IN RUSSIA AND THE REPUBLIC OF GEORGIA

Operations in Russia and the republic of Georgia ("Georgia") entail certain
risks. Recently, the former republics of the Soviet Union including Georgia have
experienced political, social and economic change as they sought independence
from the former central government in Moscow, and certain of the republics,
including Russia and Georgia, have attempted to transition from a central
controlled economy toward a market-based economy. These changes have involved,
in certain cases, armed conflict. There can be no assurance that political or
economic instability in these republics will not continue or worsen. The supply
of stable isotopes could be directly affected by political, economic and
military conditions in Russia and Georgia. Accordingly, our operations could be
materially adversely affected if hostilities in Russia should occur, if trade
between Russia or Georgia and the United States were interrupted, if political
conditions in Russia or Georgia disrupt transportation or processing concerning
our goods, if laws or government policies concerning foreign business operations
in Russia or Georgia change substantially, or if tariffs are introduced.


CUSTOMER CONCENTRATION

Historically, substantially all of our net revenues in any particular period
have been attributable to a limited number of customers. Consistent with our
historical experience, our quarterly results are expected to be affected
materially by the level of orders received and product shipments by us during
such periods. This factor pertains primarily to radioisotope sales. There can be
no assurance that our current customers will continue to purchase products. A
decrease in or loss of orders from one or more major radioisotope customers
would have a material and adverse effect on our financial condition and results
of operations.


MANAGEMENT OF GROWTH

We have experienced periods of rapid growth that have placed a significant
strain on our financial and managerial resources. Our ability to manage growth
effectively, particularly given our changing scope of operations, will require
us to continue to implement and improve our management, operational, and
financial information systems, as well as to develop the management skills of
our personnel and to train, motivate and manage our employees. Our failure to
effectively manage growth could have a material adverse effect on our business,
financial condition and results of operations.



                                       21
<PAGE>

ITEM 2:  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (CONTINUED)


DEPENDENCE ON KEY PERSONNEL

Our future success will depend in significant part upon the continued service of
our key technical, sales and senior management personnel, including James E.
Alexander, our President and Chief Executive Officer, Boris Rubizhevsky, our
Senior Vice President, Isotope Production and Supply, Dr. Robert Cuttriss,
President of Interpro, and Herbert Hegener, Managing Director of Chemotrade. We
maintain $1 million of key man life insurance on the lives of Messrs. Alexander
and Rubizhevsky, and Dr. Cuttriss and all are covered by employment agreements
with the Company extending through September 2001, 2001, and 2003, respectively.
Mr. Hegener is covered by an employment agreement with the Company extending
through the year 2001. We believe that our future success will depend in large
part upon our ability to attract and retain qualified personnel for our
operations. The failure to attract or retain such persons could materially
adversely affect our business, financial condition and results of operations.


VOLATILITY OF STOCK PRICE

The trading price of our securities has been subject to wide fluctuations in
response to quarter-to-quarter variations in operating results, announcements of
technological innovations or new products by us or our competitors, and other
events or factors. In addition, the stock market has experienced wide price and
volume fluctuations, which have at times been unrelated to the operating
performance of the companies whose securities are traded. These broad market
fluctuations may adversely effect the market price of our common stock and
common stock warrants.



                                       22
<PAGE>

ITEM 2:  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (CONTINUED)


SHARES ELIGIBLE FOR FUTURE SALE

As of March 10, 2000, there are 6,676,691 shares outstanding of our Common
Stock. An additional 11,396,668 shares of Common Stock are issuable through
the exercise of options and warrants and the conversion of our Preferred
Stock, including 4,000,000 warrants held by Eagle Picher that are contingent
on the delivery of 200 kilograms of silicon-28 by Eagle-Picher to us. Based
on the 17-3/8 per share closing price of our Common Stock on March 10, 2000,
all of our common stock equivalents are in-the-money. If the Common Stock
underlying these securities were issued, the existing holders of our Common
Stock would be subject to substantial dilution of their holdings. Because our
officers, directors and affiliates hold a significant number of these
securities, these persons would continue to control more than 50% of our
Common Stock on a fully diluted basis.

There are approximately 1.924 million shares and equivalents subject to a
lock- up agreement that expires in September 2000. Because of actions taken
by the underwriter of our initial public offering, we have the sole
discretion to release these securities from the lock-up agreement prior to
September 2000.

The warrants issued in conjunction with the private placement of convertible
preferred stock as well as the convertible preferred stock (approximately 2.33
million and 1.83 million respectively) in July 1999, are also subject to a
lock-up that expires in April 2000.

Although many of the shares issuable through the exercise of warrants or the
conversion of our Preferred Stock are not registered, the majority of the
securities are subject to registration rights agreements whereby we can be
required to register the underlying shares for resale. Once the shares are
registered, all of our outstanding Common Stock will be eligible for resale
in the open market. The offer of a large number of shares of common stock for
sale could have a negative effect on the trading price of our Common Stock.

We may call up to 4.810 million of the outstanding warrants in the event the
closing price of our Common Stock exceeds various pre-determined values for a
period of time. The call provision with the greatest restrictions requires
the closing price of our Common Stock to exceed $14.50 for twenty consecutive
trading days. If we were to exercise all our call provisions as of March 10,
2000, there would be approximately 11.487 million shares of our Common Stock
outstanding on a fully diluted basis.


                                       23
<PAGE>

                           PART II: OTHER INFORMATION


ITEM 6: EXHIBITS AND REPORTS ON FORM 8-K

We filed a report on Form 8-K and a subsequent Form 8-K/A describing the sale of
our depleted zinc business to Eagle-Picher Technologies dated December 15, 1999.



                                       24
<PAGE>

                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized, in the City of Golden, County of
Jefferson, State of Colorado, on the 14th day of March, 2000.


      Isonics Corporation
           (Registrant)



      By  /s/James E. Alexander
        -------------------------
        James E. Alexander
        President, Chief Executive Officer and Director




      By  /s/ Brantley J. Halstead
        -------------------------
        Brantley J. Halstead
        Chief Accounting Officer and Chief Financial Officer


                                       25